These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 20028385)
1. Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis. Lu X; Ohata K; Kondo Y; Espinoza JL; Qi Z; Nakao S Cancer Sci; 2010 Mar; 101(3):609-15. PubMed ID: 20028385 [TBL] [Abstract][Full Text] [Related]
2. [NKG2D-mediated natural killer cell cytotoxicity against myeloid leukemia cells OUN-1]. Lu XZ; Cai XH; Ma LD; Chen BA Zhonghua Xue Ye Xue Za Zhi; 2012 Jun; 33(6):444-7. PubMed ID: 22967377 [TBL] [Abstract][Full Text] [Related]
3. Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma. Wu X; Tao Y; Hou J; Meng X; Shi J Neoplasia; 2012 Dec; 14(12):1178-89. PubMed ID: 23308050 [TBL] [Abstract][Full Text] [Related]
4. Upregulation of CD54 and downregulation of HLA‑ABC contribute to the novel enhancement of the susceptibility of HL-60 cells to NK cell-mediated cytolysis induced by ATRA plus VPA. Zou H; Li L; Han Y; Ma R; Liao Q; Tian J; Zhang X; Ren X; Song G; Guo Q; Li X; Ding H; Jiang G Oncol Rep; 2017 Jan; 37(1):105-114. PubMed ID: 27840957 [TBL] [Abstract][Full Text] [Related]
6. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Diermayr S; Himmelreich H; Durovic B; Mathys-Schneeberger A; Siegler U; Langenkamp U; Hofsteenge J; Gratwohl A; Tichelli A; Paluszewska M; Wiktor-Jedrzejczak W; Kalberer CP; Wodnar-Filipowicz A Blood; 2008 Feb; 111(3):1428-36. PubMed ID: 17993609 [TBL] [Abstract][Full Text] [Related]
7. Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death. Yamanegi K; Yamane J; Kobayashi K; Kato-Kogoe N; Ohyama H; Nakasho K; Yamada N; Hata M; Fukunaga S; Futani H; Okamura H; Terada N Int J Oncol; 2012 Jul; 41(1):83-91. PubMed ID: 22576685 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. Hilpert J; Grosse-Hovest L; Grünebach F; Buechele C; Nuebling T; Raum T; Steinle A; Salih HR J Immunol; 2012 Aug; 189(3):1360-71. PubMed ID: 22730533 [TBL] [Abstract][Full Text] [Related]
9. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Rohner A; Langenkamp U; Siegler U; Kalberer CP; Wodnar-Filipowicz A Leuk Res; 2007 Oct; 31(10):1393-402. PubMed ID: 17391757 [TBL] [Abstract][Full Text] [Related]
10. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition. Song DG; Ye Q; Santoro S; Fang C; Best A; Powell DJ Hum Gene Ther; 2013 Mar; 24(3):295-305. PubMed ID: 23297870 [TBL] [Abstract][Full Text] [Related]
11. Valproic acid upregulates NKG2D ligand expression and enhances susceptibility of human renal carcinoma cells to NK cell-mediated cytotoxicity. Yang F; Shao Y; Yang F; Liu M; Huang J; Zhu K; Guo C; Luo J; Li W; Yang B; Shi J; Zheng J Arch Med Sci; 2013 Apr; 9(2):323-31. PubMed ID: 23671445 [TBL] [Abstract][Full Text] [Related]
12. Resveratrol sensitized leukemia stem cell-like KG-1a cells to cytokine-induced killer cells-mediated cytolysis through NKG2D ligands and TRAIL receptors. Hu L; Cao D; Li Y; He Y; Guo K Cancer Biol Ther; 2012 May; 13(7):516-26. PubMed ID: 22406996 [TBL] [Abstract][Full Text] [Related]
13. Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity. Yamanegi K; Yamane J; Kobayashi K; Kato-Kogoe N; Ohyama H; Nakasho K; Yamada N; Hata M; Nishioka T; Fukunaga S; Futani H; Okamura H; Terada N Oncol Rep; 2010 Dec; 24(6):1621-7. PubMed ID: 21042760 [TBL] [Abstract][Full Text] [Related]
14. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914 [TBL] [Abstract][Full Text] [Related]
15. Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway. Shi P; Yin T; Zhou F; Cui P; Gou S; Wang C BMC Cancer; 2014 May; 14():370. PubMed ID: 24885711 [TBL] [Abstract][Full Text] [Related]
16. Human Natural Killer cell expression of ULBP2 is associated with a mature functional phenotype. Brennan K; McSharry BP; Keating S; Petrasca A; O'Reilly VP; Keane J; Doherty DG; Gardiner CM Hum Immunol; 2016 Oct; 77(10):876-885. PubMed ID: 27349945 [TBL] [Abstract][Full Text] [Related]
17. Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D/NKG2DL activation pathway. Wu HY; Li KX; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Huang YX Int Immunopharmacol; 2022 Mar; 104():108497. PubMed ID: 34999394 [TBL] [Abstract][Full Text] [Related]
18. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Zhu S; Denman CJ; Cobanoglu ZS; Kiany S; Lau CC; Gottschalk SM; Hughes DP; Kleinerman ES; Lee DA Pharm Res; 2015 Mar; 32(3):779-92. PubMed ID: 24203492 [TBL] [Abstract][Full Text] [Related]
19. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Poggi A; Catellani S; Garuti A; Pierri I; Gobbi M; Zocchi MR Leukemia; 2009 Apr; 23(4):641-8. PubMed ID: 19151770 [TBL] [Abstract][Full Text] [Related]
20. c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells. Molfetta R; Quatrini L; Capuano C; Gasparrini F; Zitti B; Zingoni A; Galandrini R; Santoni A; Paolini R Eur J Immunol; 2014 Sep; 44(9):2761-70. PubMed ID: 24846123 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]